Novo Nordisk is taking the price-increase pledge. Three months after Allergan CEO Brent Saunders surprised pharma with a similar vow, Novo says it will limit list-price hikes to single-digit percentages annually.
On its annual list of the world’s 100 top CEOs, Harvard Business Review tagged 5 biopharma execs--and one, Novo Nordisk CEO Lars Rebien Sørensen, took the No. 1 slot for the second year in a row. Thing is, two of those 5 are on their way out.
Novo Nordisk, pressured by U.S. payers and stepped-up competition in its signature diabetes market, will lay off 1,000 people worldwide to cut costs and sharpen its focus on “truly innovative” new products.